Health & Fitness
Tue, March 13, 2012Mon, March 12, 2012Sat, March 10, 2012Fri, March 9, 2012Thu, March 8, 2012Wed, March 7, 2012Tue, March 6, 2012Mon, March 5, 2012Fri, March 2, 2012Thu, March 1, 2012Wed, February 29, 2012Discovery Labs to Hold Conference Call to Discuss FDA Approval of SURFAXIN (lucinactant)
//health-fitness.news-articles.net/content/2012/ .. iscuss-fda-approval-of-surfaxin-lucinactant.html
Published in Health and Fitness on Wednesday, March 7th 2012 at 4:56 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
Media Alert: Discovery Labs to Hold Conference Call to Discuss FDA... -- WARRINGTON, Pa., March 7, 2012 /PRNewswire/ --
Media Alert: Discovery Labs to Hold Conference Call to Discuss FDA Approval of SURFAXIN (lucinactant)
WARRINGTON, Pa., March 7, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: [ DSCO ]), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, will hold a conference call for investors today at 10 a.m. EST to discuss its March 6th announcement that SURFAXIN (lucinactant) has been approved by the FDA for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS. SURFAXIN is the first FDA-approved synthetic, peptide-containing surfactant.
The call-in number is (877) 215-0093. The international call in number is (706) 679-3237. The passcode is 58400332. This audio webcast will be available through a live broadcast on the Internet at [ http://us.meeting-stream.com/discoverylaboratories_030212 ] and [ www.discoverylabs.com ]. The replay number to hear the conference call is (855) 859-2056 or (404) 537-3406 using the same conference call password listed above.
IMPORTANT SAFETY INFORMATION
SURFAXIN (lucinactant intratracheal suspension) is intended for intratracheal use only. The administration of exogenous surfactants, including SURFAXIN, can rapidly affect oxygenation and lung compliance. SURFAXIN should be administered only by clinicians trained and experienced with intubation, ventilator management, and general care of premature infants in a highly supervised clinical setting. Infants receiving SURFAXIN should receive frequent clinical assessments so that oxygen and ventilatory support can be modified to respond to changes in respiratory status.
Most common adverse reactions associated with the use of SURFAXIN are endotracheal tube reflux, pallor, endotracheal tube obstruction, and need for dose interruption. During SURFAXIN administration, if bradycardia, oxygen desaturation, endotracheal tube reflux, or airway obstruction occurs, administration should be interrupted and the infant's clinical condition assessed and stabilized. SURFAXIN is not indicated for use in acute respiratory distress syndrome (ARDS).
For more information about SURFAXIN, please visit [ www.surfaxin.com ].
SOURCE Discovery Laboratories Inc.
[ Back to top ] RELATED LINKS
[ http://www.discoverylabs.com ]
